180 Life Sciences Corp. (ATNF)

NASDAQ: ATNF · IEX Real-Time Price · USD
2.330
+0.320 (15.92%)
At close: Mar 28, 2024, 4:00 PM
2.210
-0.120 (-5.15%)
After-hours: Mar 28, 2024, 7:57 PM EDT

Company Description

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases.

The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.

180 Life Sciences Corp. is headquartered in Palo Alto, California.

180 Life Sciences Corp.
180 Life Sciences logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 5
CEO Dr. James N. Woody M.D., Ph.D.

Contact Details

Address:
3000 El Camino Real, Bldg 4, Ste 200
Palo Alto, California 94306
United States
Phone 650-507-0669
Website 180lifesciences.com

Stock Details

Ticker Symbol ATNF
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690080
CUSIP Number 68236V104
ISIN Number US68236V3024
Employer ID 81-3832378
SIC Code 2834

Key Executives

Name Position
Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder and Executive Chairman
Dr. James N. Woody M.D., Ph.D. Chief Executive Officer and Director
Ozan Pamir C.F.A. Chief Financial Officer and Secretary
Dr. Jonathan B. Rothbard Ph.D. Chief Scientific Officer
Prof. Jagdeep Nanchahal Co-Founder and Chairman of Clinical Advisory Board
Jason Assad Director of IR

Latest SEC Filings

Date Type Title
Mar 25, 2024 10-K Annual Report
Mar 14, 2024 8-K Current Report
Mar 11, 2024 8-K Current Report
Mar 8, 2024 8-K Current Report
Mar 1, 2024 8-K Current Report
Feb 29, 2024 8-K Current Report
Feb 28, 2024 424B3 Prospectus
Feb 28, 2024 424B3 Prospectus
Feb 28, 2024 424B3 Prospectus
Feb 28, 2024 8-K Current Report